Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.
Kirken
R A
RA
Department of Integrative Biology and Pharmacology, University of Texas-Houston, Houston, Texas, USA.
Erwin-Cohen
R
R
Behbod
F
F
Wang
M
M
Stepkowski
S M
SM
Kahan
B D
BD
D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D053616:Janus Kinase 3; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D011912:Rats, Inbred ACI; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000187:drug effects* / Q000201:enzymology; D014184:Transplantation, Homologous; D020032:Tyrphostins / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D007376:Interleukin-2; C507936:Jak3 protein, rat; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; D016572:Cyclosporine; D011505:Protein-Tyrosine Kinases; D053616:Janus Kinase 3